This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday - Centene (NY

This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday - Centene (NY

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Mitchell S. Kapoor downgraded Summit Therapeutics Inc (NASDAQ:SMMT) from Buy to Neutral. Summit Therapeutics shares closed at $17.47 on Thursday. See how other ...Full story available on Benzinga.com

Summit downgraded after Merck data for sac-TMT (SMMT:NASDAQ)

Summit Therapeutics (SMMT) stock faced a downgrade at H.C. Wainwright after late-stage trial data for Merck’s (MRK) lung cancer drug sac-TMT. Read more here.

Friday’s analyst upgrades and downgrades

Inside the Market’s roundup of some of today’s key analyst actions

In Case You Missed It - BC Extra Upgrades & Downgrades

A summary of the highlights from Broker Call Extra updates throughout the week past